Jounce Therapeutics to Present Nonclinical Translational Data at the 2018 American Association for Cancer Research (AACR) Ann...
April 12 2018 - 8:00AM
Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers for patient enrichment,
today announced that its nonclinical translational data will be
presented in two posters at the 2018 American Association for
Cancer Research (AACR) Annual Meeting in Chicago, Illinois from
April 14-18, 2018.
“The data presented at AACR for gastric cancer and triple
negative breast cancer provides an example of the way in which we
use the Jounce Translational Science Platform to interrogate the
cellular microenvironment within the tumor to explore potential
biomarkers. These data, focused on our ICOS agonist antibody
program, JTX-2011, help inform our clinical development strategy,”
said Deborah Law, D. Phil., chief scientific officer of Jounce
Therapeutics.
Details on the posters are as follows:
Genomics based studies of gastric tumors identify ICOS
as potential target for therapeutic interventionSession
Title: Immune Checkpoints 1Location: McCormick Place South, Exhibit
Hall A, Poster Section 31Date and Time: Monday Apr 16, 2018 from
8:00 AM - 12:00 PM CTPoster Board Number: 10; Permanent Abstract
Number: 1685
Integrated genomics and histology based studies of
triple negative breast cancer identify ICOS as potential target for
therapeutic interventionSession Title: Immune
Checkpoints 1Location: McCormick Place South, Exhibit Hall A,
Poster Section 31Date and Time: Monday Apr 16, 2018 from 8:00 AM -
12:00 PM CTPoster Board Number: 3; Permanent Abstract Number:
1678
The posters will be available on the “Investors and Media”
section of the Jounce Therapeutics website at www.jouncetx.com.
About JTX-2011Jounce’s lead product candidate,
JTX-2011, is a monoclonal antibody that binds to and activates
ICOS, a protein on the surface of certain T cells. Preclinical data
support that JTX-2011 may have a dual mechanism of action that
stimulates anti-tumor T effector cells, and also reduces the
immunosuppressive T regulatory cells in the tumor microenvironment.
The company is developing JTX-2011 to treat solid tumors as a
single agent and in combination with other therapies.
About Jounce TherapeuticsJounce Therapeutics,
Inc. is a clinical stage immunotherapy company dedicated to
transforming the treatment of cancer by developing therapies that
enable the immune system to attack tumors and provide long‑lasting
benefits to patients. Through the use of its Translational Science
Platform, Jounce first focuses on specific cell types within tumors
to prioritize targets, and then identifies related biomarkers
designed to match the right therapy to the right patient. Jounce’s
lead product candidate, JTX-2011, is a monoclonal antibody that
binds to and activates ICOS and is currently in the Phase 2 portion
of the Phase 1/2 ICONIC trial. For more information, please visit
www.jouncetx.com.
Forward Looking StatementsStatements in this
release concerning Jounce’s future expectations and plans,
including without limitation, Jounce’s expectations regarding the
timing, progress and results of preclinical studies and clinical
trials for Jounce’s product candidates and Jounce’s clinical
development strategy may constitute forward looking statements for
the purposes of the safe harbor provisions under The Private
Securities Litigation Reform Act of 1995 and other federal
securities laws and are subject to substantial risks, uncertainties
and assumptions. You should not place reliance on these forward
looking statements, which include words such as “may,” “potential”
or similar terms, variations of such terms or the negative of those
terms. Although the Company believes that the expectations
reflected in the forward-looking statements are reasonable, the
Company cannot guarantee such outcomes. Actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors, as well as those risks
more fully discussed in the section entitled “Risk Factors” in
Jounce’s most recent annual report on Form 10-K, as well as
discussions of potential risks, uncertainties, and other important
factors in Jounce’s subsequent filings with the U.S. Securities and
Exchange Commission. All such statements speak only as of the date
made, and the Company undertakes no obligation to update or revise
publicly any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Contact:Komal JoshiJounce
Therapeutics, Inc.(857) 320-2523kjoshi@jouncetx.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Apr 2023 to Apr 2024